Jamal Suleiman
Instituto de Infectologia Emílio Ribas(BR)
Publications by Year
Research Areas
HIV/AIDS drug development and treatment, HIV Research and Treatment, HIV/AIDS Research and Interventions, HIV-related health complications and treatments, Antifungal resistance and susceptibility
Most-Cited Works
- → A Randomized, Double-Blind, Parallel-Group, Dose-Response Study of Micafungin Compared with Fluconazole for the Treatment of Esophageal Candidiasis in HIV-Positive Patients(2004)205 cited
- → The Safety and Efficacy of Tenofovir DF in Combination with Lamivudine and Efavirenz Through 6 Years in Antiretroviral-Naïve HIV-1—Infected Patients(2007)167 cited
- → A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis(2005)146 cited
- → Oral colonization by yeasts in HIV-positive patients in Brazil(2012)105 cited
- → Genetic heterogeneity of the V3 region of the HIV-1 envelope glycoprotein in Brazil(1993)93 cited
- → Photodynamic inactivation of biofilms formed by Candida spp., Trichosporon mucoides, and Kodamaea ohmeri by cationic nanoemulsion of zinc 2,9,16,23-tetrakis(phenylthio)-29H, 31H-phthalocyanine (ZnPc)(2012)71 cited
- → The Safety and Efficacy of Switching Stavudine to Tenofovir DF in Combination with Lamivudine and Efavirenz in HIV-1—Infected Patients: Three-Year Follow–up After Switching Therapy(2007)61 cited
- Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive Patients(2004)
- → Trypanosoma cruzi Meningoencephalitis in HIV-Infected Patients(1999)57 cited
- → Vicriviroc in Combination Therapy with an Optimized Regimen for Treatment‐Experienced Subjects: 48‐Week Results of the VICTOR‐E1 Phase 2 Trial(2010)44 cited